AndreaBozzo/ceres-open-data-index huggingface dataset:
MD iMAP: Maryland Community Health Resource Commission - Jurisdiction Grantee Totals

This is a MD iMAP hosted service. Find more information at  http://imap.maryland.gov. Jurisdiction Grantee Totals - Aggregate totals 2007-2014.Feature Service Link:http://geodata.md.gov/imap/rest/services/Health/MD_CommunityHealthResourceCommission/FeatureServer/8 ADDITIONAL LICENSE TERMS: The Spatial Data and the information therein (collectively "the Data") is provided "as is" without warranty of any kind either expressed implied or statutory. The user assumes the entire risk as to quality and performance of the Data. No guarantee of accuracy is granted nor is any responsibility for reliance thereon assumed. In no event shall the State of Maryland be liable for direct indirect incidental consequential or special damages of any kind. The State of Maryland does not accept liability for any damages or misrepresentation caused by inaccuracies in the Data or as a result to changes to the Data nor is there responsibility assumed to maintain the Data in any manner or form. The Data can be freely distributed as long as the metadata entry is not modified or deleted. Any data derived from the Data must acknowledge the State of Maryland in the metadata.
Patent AT-E401336-T1: [Translated] COMPLEXES OF RUTHENIUM WITH 2-(AMINOMETHYL)PYRIDINES AND PHOSPHINES, THEIR PREPARATION AND USE AS CATALYSTS

The invention relates to a new class of ruthenium (II) complexes containing as ligands 2-(aminomethyl)pyridines and phosphines, proven to be extremely active catalysts in the reduction of ketones to alcohols via hydrogen transfer. By using 2-propanol as the hydrogen source with the ruthenium complexes, high yields of the corresponding alcohol can be rapidly obtained starting from linear and cyclic alkyl aryl, dialkyl and diaryl ketones. The conversion of ketones to alcohols can reach 100% if operating in a gaseous hydrogen atmosphere (2-3 atm). Where the phosphines used are optically active, starting from prochiral ketone compounds various types of optically active alcohols can be produced, being important intermediates in the pharmaceutical industry, in the agrochemical industry and for fine chemicals generally.
Insight to structural subsite recognition in plant thiol protease-inhibitor complexes : Understanding the basis of differential inhibition and the role of water

Background
          This work represents an extensive MD simulation / water-dynamics studies on a series of complexes of inhibitors (leupeptin, E-64, E-64-C, ZPACK) and plant cysteine proteases (actinidin, caricain, chymopapain, calotropin DI) of papain family to understand the various interactions, water binding mode, factors influencing it and the structural basis of differential inhibition.
        
        
          Results
          The tertiary structure of the enzyme-inhibitor complexes were built by visual interactive modeling and energy minimization followed by dynamic simulation of 120 ps in water environment. DASA study with and without the inhibitor revealed the potential subsite residues involved in inhibition. Though the interaction involving main chain atoms are similar, critical inspection of the complexes reveal significant differences in the side chain interactions in S2-P2 and S3-P3 pairs due to sequence differences in the equivalent positions of respective subsites leading to differential inhibition.
        
        
          Conclusion
          The key finding of the study is a conserved site of a water molecule near oxyanion hole of the enzyme active site, which is found in all the modeled complexes and in most crystal structures of papain family either native or complexed. Conserved water molecules at the ligand binding sites of these homologous proteins suggest the structural importance of the water, which changes the conventional definition of chemical geometry of inhibitor binding domain, its shape and complimentarity. The water mediated recognition of inhibitor to enzyme subsites (Pn...H2O....Sn) of leupeptin acetyl oxygen to caricain, chymopapain and calotropinDI is an additional information and offer valuable insight to potent inhibitor design.
Compound 529114: 4-Quinazolone, 2-methyl-3-propyl

Chemical compound data from PubChem database. IUPAC Name: 2,3-dipropylquinazolin-4-one. Molecular Formula: C14H18N2O. Molecular Weight: 230.31. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Research Article: BMC Medical Genetics

Background
          Since contradictory results have been reported, we reanalysed the 77C→G transition in exon 4 of the protein-tyrosine phosphatase receptor-type C (PTPRC also known as CD45) in a large cohort of German MS patients and controls. Different isoforms of the protein are expressed, depending on alternative splicing of exons 4 (CD45RA), 5 (CD45RB) and 6 (CD45RC) (CD45RO, exons 4–6 spliced out). The 77C→G transition does not change the amino acid sequence, but it is probably part of a motif necessary for splicing leading to the isoform CD45RA. The expression of CD45RA is increased in 77C/G heterozygous individuals. The aim of the study was to clarify the importance of the PTPRC 77C→G transition in our German cohort of MS patients.
        
        
          Methods
          PCR products of exon 4 were digested using endonuclease MspI. The resulting restriction fragments of the wildtype C allele are 198 and 62 bp in length. In the G allele an additional restriction site is present yielding fragments of 114 and 84 bp.
        
        
          Results
          The G allele was identified in 10 of the 347 controls (1.4%) and in 7 of 454 MS patients (0.8%; Table 1). No homozygous individuals were found either in the control or in the patient group. Genetic association between the PTPRC 77C→G transition and MS susceptibility was excluded in the MS cohort. In addition, subgrouping patients according to differences in the clinical course of MS or according to HLA-DRB1*15 status did not yield significant differences.
        
        
          Conclusions
          The 77C→G transition in exon 4 of the PTPRC gene may contribute to MS susceptibility only in very few families, if at all, but it is not relevant for the majority of MS cases, including virtually all German patients.
Patent AT-E39999-T1: [Translated] DEVICE FOR HEATING DOMESTIC WATER BY SOLAR ENERGY.

The invention relates to an apparatus for heating water by solar energy, including a container made from a plastic film or sheeting for the water to be supplied to consumers, having a cold water inlet opening preceded by an inlet valve and having a withdrawal opening, wherein the top of the container is transparent and the bottom is dark in color. To further develop a known apparatus of this type such that water can be withdrawn even for relatively large-scale needs and it can be connected to an installed water system, it is provided that the outlet opening is followed by a pump and a check valve, that the inlet valve is electromagnetically actuatable, and that a sensor for measuring the instantaneous water temperature and an adjusting device for adjusting the desired temperature of the water to be supplied are connected to the inlet valve. The higher the instantaneous water temperature, the more cold water the inlet valve admits into the container.
Surgical Site Infections (SSIs) for Operative Procedures in California Hospitals

These datasets show surgical site infections (SSIs) reported by California hospitals to the California Department of Public Health (CDPH), Healthcare-Associated Infections (HAI) Program, via the Centers for Disease Control and Prevention National Healthcare Safety Network (NHSN), in accordance with Health and Safety Code (HSC) section 1288.55. 

California hospitals track and report deep incisional and organ/space SSIs for adults and pediatric (<18 years of age) patients for 28 types of operative procedures: 
abdominal aortic aneurysm repair; abdominal hysterectomy; appendix surgery; bile duct, liver or pancreatic surgery, cardiac surgery; Cesarean section; colon surgery; coronary artery bypass graft with both chest and donor site incisions; coronary artery bypass graft with chest incision only*; exploratory abdominal surgery (laparotomy); gallbladder surgery; gastric surgery; heart transplant; hip prosthesis; kidney surgery; kidney transplant; knee prosthesis; laminectomy; liver transplant; open reduction of fracture; ovarian surgery; pacemaker surgery; rectal surgery; small bowel surgery; spinal fusion; spleen surgery; thoracic surgery; vaginal hysterectomy 

The SSI data tables include information on the statewide and hospital-specific SSI incidence by operative procedure types, displaying procedure counts, number of infections observed (reported) and predicted. NHSN calculates the number of predicted infections using procedure-specific risk adjustment logistic regression models based on 2015 national baseline data and that accounts for particular patient-level factors and hospital characteristics found to be significant predictors of SSI incidence. 

Detailed information about the variables included in each dataset are described in the accompanying data dictionaries for the year of interest. For more information about NHSN’s statistical models, please review the “NHSN Guide to the SIR” at https://www.cdc.gov/nhsn/ps-analysis-resources/index.html

To link the CDPH facility IDs with those from other Departments, like HCAI, please refer to the "Licensed Facility Cross-Walk" Open Data table at https://data.chhs.ca.gov/dataset/licensed-facility-crosswalk

For more information about HAIs in California hospitals, please visit: https://www.cdph.ca.gov/Programs/CHCQ/HAI/Pages/AnnualHAIReports.aspx
Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease

Background
          Fabry disease is a lysosomal X-linked enzyme deficiency of α-galactosidase A associated with an increased mortality and morbidity due to renal failure, cardiac disease and early onset stroke.
        
        
          Methods
          We examined the functional blood flow response of the brain after visual stimulation (reversing checkerboard pattern), and cerebral vasoreactivity following acetazolamide (15 mg/kg) with [15O]H2O and positron emission tomography (PET) in Fabry disease. Twenty-six hemizygous patients (age range 19–47 years) were enrolled in a randomized double-blind placebo-controlled 6-month trial of enzyme replacement therapy administered by intravenous infusion every two weeks. Regional cerebral blood flow (rCBF) was measured with PET at the beginning and end of the trial.
        
        
          Results
          Fabry patients had a significantly greater increase in rCBF following visual stimulation and acetazolamide challenge compared to controls. Visual reactivity was normal. The time for recovery of the cerebral vasculature following acetazolamide was prolonged in Fabry patients compared to controls. The abnormal rCBF response induced by visual stimulation and acetazolamide decreased significantly following enzyme replacement therapy, as did the prolonged recovery of the cerebral vasculature.
        
        
          Conclusions
          Enzyme replacement therapy reverses the exaggerated cerebrovascular response in Fabry disease.
Kansas 2016 Potential Areas for Addressing Service Gaps for Opioid Treatment

The purpose of the medication-assisted treatment (MAT) facility maps is to identify areas on a state-by-state basis that may be potentially underserved by existing treatment facilities. The maps are created with a methodology that seeks to include the highest potential need areas from individual counties so that county-level stakeholders are also informed. The maps are meant to be used as a tool for policy makers to determine potentially underserved areas—not as a definitive representation of these areas.
Compound 528951: Phenol, 2-(1-ethylpropyl)-6-nitro

Chemical compound data from PubChem database. IUPAC Name: 2-nitro-6-pentan-3-ylphenol. Molecular Formula: C11H15NO3. Molecular Weight: 209.24. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
National Directory of Drug Abuse Treatment Facilities - 1980

The National Directory of Drug Abuse Treatment Programs 1980 lists federal, state, local, and private facilities that provide substance abuse treatment services. The directory includes treatment facilities that are licensed, certified, or otherwise approved for inclusion in the directory by their state substance abuse agencies and that responded to the 1979 National Survey of Substance Abuse Treatment Services (N-SSATS). The information about each facility that appears in this directory was provided by that facility in response to the 1979 N-SSATS. The Substance Abuse and Mental Health Services Administration (SAMHSA) conducts the N-SSATS annually.
Prednisolone sodium phosphate

Prednisolone Sodium Phosphate is a prescription oral solution, a generic corticosteroid medication used to reduce inflammation and treat conditions like allergies, arthritis, and certain skin disorders. Each 5 mL contains the equivalent of 20 mg of prednisolone base. Manufactured by PAI Holdings, LLC dba PAI Pharma. This information was generated using AI and is provided for informational and research purposes only.
Differential clinical efficacy of anti-CD4 monoclonal antibodies in rat adjuvant arthritis is paralleled by differential influence on NF-κB binding activity and TNF-α secretion of T cells

The aim of this study was to analyze the differential effects of three anti-CD4 monoclonal antibodies (mAbs) (with distinct epitope specifities) in the treatment of rat adjuvant arthritis (AA) and on T-cell function and signal transduction. Rat AA was preventively treated by intraperitoneal injection of the anti-CD4 mAbs W3/25, OX35, and RIB5/2 (on days -1, 0, 3, and 6, i.e. 1 day before AA induction, on the day of induction [day 0], and thereafter). The effects on T-cell reactivity in vivo (delayed-type hypersensitivity), ex vivo (ConA-induced proliferation), and in vitro (mixed lymphocyte culture) were assessed. The in vitro effects of anti-CD4 preincubation on T-cell receptor (TCR)/CD3-induced cytokine production and signal transduction were also analyzed. While preventive treatment with OX35 and W3/25 significantly ameliorated AA from the onset, treatment with RIB5/2 even accelerated the onset of AA by approximately 2 days (day 10), and ameliorated the arthritis only in the late phase (day 27). Differential clinical effects at the onset of AA were paralleled by a differential influence of the mAbs on T-cell functions, i.e. in comparison with OX35 and W3/25, the 'accelerating' mAb RIB5/2 failed to increase the delayed-type hypersentivity (DTH) to Mycobacterium tuberculosis, increased the in vitro tumor necrosis factor (TNF)-α secretion, and more strongly induced NF-κB binding activity after anti-CD4 preincubation and subsequent TCR/CD3-stimulation. Depending on their epitope specificity, different anti-CD4 mAbs differentially influence individual proinflammatory functions of T cells. This fine regulation may explain the differential efficacy in the treatment of AA and may contribute to the understanding of such treatments in other immunopathologies.
Patent AT-E401495-T1: [Translated] SYSTEM FOR SUPPORTING THE REGENERATION OF MOTOR VEHICLE EXHAUST TOXICANTS

If the exothermic activity of the catalyst exceeds a safety threshold value during application of a second, higher temperature regeneration strategy, the fuel feed is controlled to reduce it progressively; if it is above the threshold after a first period the feed switches to a first strategy and if it is still above the threshold after a second period the regeneration is stopped. System for helping the regeneration of means of depollution (1) associated with an oxidation catalyst (2) and integrated into the exhaust pipe (3) of a vehicle's Diesel engine (4). The engine is connected to a common fuel feed injecting fuel into all the cylinders, in the manner of a post-injection. At least two regeneration strategies are put into operation by isocouple at a first and second level (10, 11) depending on the different engine operating control parameters to obtain different heat levels in the exhaust pipe. The heat level corresponding to the second level strategy (10) is greater than that of the first level strategy (11). The fuel feed is designed to operate two successive post-injections. During regulation, the fuel feed is designed to progressively reduce the flow of fuel in the second injection using a correction factor between 0 and 1 determined from the gap between the exothermic level (NT) and the safety threshold value (seuil-secu) by a non-linear gain PI regulator. The means of recording the exothermic level are two temperature detectors (9a, 9b) upstream and downstream of the catalyst. The engine is a diesel engine associated with a turbocompressor. The threshold safety value can be calibrated. The means of depollution include a particle filter and/or NOx trap and/or SOx trap and/or oxidation catalyst. The fuel includes an additive designed to be deposited onto the means of depollution with the particles with which it is mixed to aid regeneration, or an additive which forms a NOx trap.
2012 Sample Design Report

This report describes the sample design to the 2012 National Survey on Drug Use and Health (NSDUH). A coordinated sample design was developed for the 2005 through 2009 NSDUHs. The 2010-2011 and 2012-2013 samples are extensions of the 5-year sample. This report describes the general sample allocation procedures for the main NSDUH study, the NSDUH\'s Mental Health Surveillance Study, and the Questionnaire Field Test.
Patent AT-E39985-T1: [Translated] PIPE CLAMP.

1. A hingeable pipe clamp for detachably holding or holding together parts, such as rods, pipes, tubes, pipe sections or the like, the pipe clamp having two pipe clamp parts pivotably connected together by a hinge and each having a one-piece strip, the strip forming the half-shell, one or more gudgeons, and the flange of the respective pipe clamp part, a hinge pin being inserted in the gudgeons of the two pipe clamp parts, characterized in that the strip (27; 27') is arranged in a two-ply manner in the region of the flange (23; 23') and the half-shell (24; 24') of the respective pipe clamp part (22; 22'), and in that these two layers (31, 31'; 32, 32') are connected together by at least one single-ply region of the strip (27; 27') curved to form a gudgeon (26; 26').
Outpatient and Ambulatory Surgery Consumer Assessment of Healthcare Providers and Systems (OAS CAHPS) survey for ambulatory surgical centers - Facility

A list of ambulatory surgical center ratings for the Outpatient and Ambulatory Surgery Consumer Assessment of Healthcare Providers and Systems (OAS CAHPS) survey. The OAS CAHPS survey collects information about patients' experiences of care in hospital outpatient departments (HOPDs) and ambulatory surgical centers (ASCs). The data are updated and reported each quarter with data from the most recently completed quarter replacing the oldest quarter of data.
Public Health Statistics - Life Expectancy By Community Area - Historical

Note: This dataset is historical only and there are not corresponding datasets for more recent time periods. For that more-recent information, please visit the Chicago Health Atlas at https://chicagohealthatlas.org.

This dataset gives the average life expectancy and corresponding confidence intervals for each Chicago community area for the years 1990, 2000 and 2010.  See the full description at: https://data.cityofchicago.org/api/views/qjr3-bm53/files/AAu4x8SCRz_bnQb8SVUyAXdd913TMObSYj6V40cR6p8?download=true&filename=P:\EPI\OEPHI\MATERIALS\REFERENCES\Life Expectancy\Dataset description - LE by community area.pdf
Compound 526465: Pentyl perfluorohexanoate

Chemical compound data from PubChem database. IUPAC Name: pentyl 2,2,3,3,4,4,5,5,6,6,6-undecafluorohexanoate. Molecular Formula: C11H11F11O2. Molecular Weight: 384.19. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E401750-T1: [Translated] REGISTRATION IN A BROADCAST COMMUNICATIONS SYSTEM

Systems and techniques are disclosed relating to communications. The systems and techniques include an input device, generating a time period in response to a broadcast channel selection from the input device, generating a request to register the broadcast channel if the time period ends before receiving a second broadcast channel selection, and transmitting the request to an access network. It is emphasized that this abstract is provided to comply with the rules requiring an abstract which will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or the meaning of the claims.
Compound 529008: Cytosine, 5-bromo-N,O-bis(trimethylsilyl)-

Chemical compound data from PubChem database. IUPAC Name: 5-bromo-N-trimethylsilyl-2-trimethylsilyloxypyrimidin-4-amine. Molecular Formula: C10H20BrN3OSi2. Molecular Weight: 334.36. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 527593: 3-Buten-1-ol, dichloroacetate

Chemical compound data from PubChem database. IUPAC Name: but-3-enyl 2,2-dichloroacetate. Molecular Formula: C6H8Cl2O2. Molecular Weight: 183.03. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E400894-T1: [Translated] COOLED ELECTRONIC ARRANGEMENT AND METHOD FOR COOLING A CIRCUIT BOARD

A cooled electronic assembly includes an integrated-circuit device carrier (such as a printed circuit board), a device (such as a flip chip), a liquid pump, a molding material, a heat exchanger, and a cover. The device and the liquid pump are electrically connected to the integrated-circuit device carrier. The molding material is molded to the device, to the liquid pump, and to the integrated-circuit device carrier. The cover has a coolant channel fluidly connected to the heat exchanger, wherein the cover is attached to the molding material. The coolant channel and the heat exchanger together at least partially define a closed coolant circuit. The liquid pump is operatively connected to the closed coolant circuit. A method for cooling a printed circuit board includes placing a liquid coolant in the closed coolant circuit and electrically activating the liquid pump through the printed circuit board.
Residence of individuals experiencing homelessness prior to enrollment in Projects for Assistance in Transition from Homelessness (PATH) program: Findings from the 2023 PATH Evaluation

This spotlight highlights a notable finding from the evaluation of SAMHSA’s Projects for Assistance in Transition from Homelessness (PATH) program published in 2024. The PATH program is intended to reduce homelessness among persons experiencing severe mental illness or co-occurring mental illness and substance use disorders. PATH collects data on the reported residence of clients the night prior to enrolling in services. An examination of these data for FY 2019 to 2021 revealed an approximately ten-point percentage increase of PATH clients reporting being in an unsheltered situation the night prior to enrollment.